670 related articles for article (PubMed ID: 22147380)
1. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
Nguyen PL; Je Y; Schutz FA; Hoffman KE; Hu JC; Parekh A; Beckman JA; Choueiri TK
JAMA; 2011 Dec; 306(21):2359-66. PubMed ID: 22147380
[TBL] [Abstract][Full Text] [Related]
2. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
[TBL] [Abstract][Full Text] [Related]
3. Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review.
Liang Z; Zhu J; Chen L; Xu Y; Yang Y; Hu R; Zhang W; Song Y; Lu Y; Ou N; Liu X
Andrology; 2020 May; 8(3):559-574. PubMed ID: 31743594
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.
Jin C; Fan Y; Meng Y; Shen C; Wang Y; Hu S; Cui C; Xu T; Yu W; Jin J
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):333-339. PubMed ID: 27595915
[TBL] [Abstract][Full Text] [Related]
5. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis.
Guo Z; Huang Y; Gong L; Gan S; Chan FL; Gu C; Xiang S; Wang S
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):451-460. PubMed ID: 29988099
[TBL] [Abstract][Full Text] [Related]
6. Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death.
Sanford NN; Chen MH; Loffredo M; Renshaw A; Kantoff PW; D'Amico AV
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):79-84. PubMed ID: 27824043
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis.
Carneiro A; Sasse AD; Wagner AA; Peixoto G; Kataguiri A; Neto AS; Bianco BA; Chang P; Pompeo AC; Tobias-Machado M
World J Urol; 2015 Sep; 33(9):1281-9. PubMed ID: 25387877
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
Botrel TE; Clark O; Lima Pompeo AC; Horta Bretas FF; Sadi MV; Ferreira U; Borges Dos Reis R
PLoS One; 2016; 11(6):e0157660. PubMed ID: 27308831
[TBL] [Abstract][Full Text] [Related]
9. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.
Abufaraj M; Iwata T; Kimura S; Haddad A; Al-Ani H; Abusubaih L; Moschini M; Briganti A; Karakiewicz PI; Shariat SF
Eur Urol; 2021 Jan; 79(1):44-53. PubMed ID: 32605859
[TBL] [Abstract][Full Text] [Related]
10. Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis.
Nead KT; Sinha S; Yang DD; Nguyen PL
Urol Oncol; 2017 Nov; 35(11):664.e1-664.e9. PubMed ID: 28803700
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.
Lapi F; Azoulay L; Niazi MT; Yin H; Benayoun S; Suissa S
JAMA; 2013 Jul; 310(3):289-96. PubMed ID: 23860987
[TBL] [Abstract][Full Text] [Related]
12. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
13. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
Taylor LG; Canfield SE; Du XL
Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
Voog JC; Paulus R; Shipley WU; Smith MR; McGowan DG; Jones CU; Bahary JP; Zeitzer KL; Souhami L; Leibenhaut MH; Rotman M; Husain SM; Gore E; Raben A; Chafe S; Sandler HM; Efstathiou JA
Eur Urol; 2016 Feb; 69(2):204-10. PubMed ID: 26362090
[TBL] [Abstract][Full Text] [Related]
16. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
Higano CS
Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
[TBL] [Abstract][Full Text] [Related]
18. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer.
Ziehr DR; Chen MH; Zhang D; Braccioforte MH; Moran BJ; Mahal BA; Hyatt AS; Basaria SS; Beard CJ; Beckman JA; Choueiri TK; D'Amico AV; Hoffman KE; Hu JC; Martin NE; Sweeney CJ; Trinh QD; Nguyen PL
BJU Int; 2015 Sep; 116(3):358-65. PubMed ID: 25124891
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.
Zhao J; Zhu S; Sun L; Meng F; Zhao L; Zhao Y; Tian H; Li P; Niu Y
PLoS One; 2014; 9(9):e107516. PubMed ID: 25264674
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]